Pieris Pharmaceuticals Intrinsic Value Calculator – Pieris Pharmaceuticals Reports Earnings Results for Q2 FY2023
August 12, 2023
🌥️Earnings Overview
On August 10 2023, PIERIS PHARMACEUTICALS ($NASDAQ:PIRS) reported their earnings results for the second quarter of FY2023 ending June 30 2023. The total revenue for the period was USD 20.1 million, a massive 437.8% increase from the same quarter of the previous year (USD 3.7 million). Net income also experienced notable growth, with a 138.5% increase to USD 4.0 million compared to the same quarter of the prior year.
Price History
According to the latest report from Pieris Pharmaceuticals, the company reported a strong earnings result for Q2 FY2023. On Thursday, its stock opened at $0.2 and closed at $0.2, up by 3.0% from the prior closing price of $0.2. This is a testament to the company’s strong performance in the second quarter of the financial year. Pieris Pharmaceuticals has been making great progress in its drug development pipeline, with an emphasis on anticalin-based therapies for cancer and respiratory diseases.
The company has also expanded its clinical trial programs for pipeline candidates and is actively engaged in collaborations with leading pharmaceutical companies. This is a positive sign that the company is on track to achieve its long-term goals and objectives in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Pieris Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 33.21 | -27.05 | -81.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pieris Pharmaceuticals. More…
| Operations | Investing | Financing |
| -46.14 | 17.11 | 20.16 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pieris Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 87.54 | 47.05 | 0.49 |
Key Ratios Snapshot
Some of the financial key ratios for Pieris Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -16.4% | – | -86.3% |
| FCF Margin | ROE | ROA |
| -139.4% | -64.0% | -20.5% |
Analysis – Pieris Pharmaceuticals Intrinsic Value Calculator
At GoodWhale, we strive to provide our users with the most accurate analysis of PIERIS PHARMACEUTICALS‘ financials. After thorough investigation, our proprietary Valuation Line has determined that the fair value of PIERIS PHARMACEUTICALS stock is around $2.0. At the time of writing, however, PIERIS PHARMACEUTICALS’ stock is being traded at a much lower price of $0.2 – an 89.9% undervaluation. This could be a great opportunity for investors to get in on the ground floor and take advantage of a stock that is trading far below its market value. More…
Peers
Some of its competitors are Aurinia Pharmaceuticals Inc, Processa Pharmaceuticals Inc, and aTyr Pharma Inc.
– Aurinia Pharmaceuticals Inc ($NASDAQ:AUPH)
Aurinia Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune diseases. The company’s lead product candidate is voclosporin, an immunosuppressant that is being developed for the treatment of lupus nephritis. The company’s other product candidates include an anti-TNF antibody and a JAK inhibitor.
– Processa Pharmaceuticals Inc ($NASDAQ:PCSA)
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel pharmaceuticals to treat conditions associated with the process of vascularization. The company was founded by Charles J. Fisher on March 10, 2011 and is headquartered in Blue Bell, PA.
– aTyr Pharma Inc ($NASDAQ:LIFE)
Tyr Pharma Inc is a pharmaceutical company with a market cap of 71.28M as of 2022. The company’s return on equity is -27.9%. Tyr Pharma Inc is a biopharmaceutical company that focuses on developing and commercializing innovative medicines for patients with serious medical conditions.
Summary
PIERIS PHARMACEUTICALS had a strong second quarter in FY2023, ending June 30th, 2023, with total revenue of USD 20.1 million, representing a tremendous 437.8% increase from the same period last year. Net income for the quarter also increased 138.5% from the same period last year to USD 4.0 million. These results led to a positive reaction in the stock price on the same day. For investors considering investing in PIERIS PHARMACEUTICALS, the company’s impressive financial performance and promising outlook suggest it could be an attractive investment opportunity.
Related Posts
Recent Posts
